The abnormal aberrant activation of the JAK/STAT signaling pathway is associated with the development of AML (Venugopal, Bar-Natan & Mascarenhas, 2020), and JAK2 inhibitors can reverse this effect (Habbel et al., 2020; Moser et al., 2021). This evidence concerns the gene JAK2 and acute myeloid leukemia.